Purpose of Review The crosstalk between the gut and the brain has revealed a complex communication system responsible for maintaining a proper gastrointestinal homeostasis as well as affect emotional mood and cognitive functions. Recent research has revealed that beneficial manipulation of the microbiota by probiotics and prebiotics represents an emerging and novel strategy for the treatment of a large spectrum of diseases ranging from visceral pain to mood disorders. The review critically evaluates current knowledge of the effects exerted by both probiotics and prebiotics in irritable bowel syndrome (IBS) and mood disorders such as anxiety and depression. Recent Findings Relevant literature was identified through a search of MEDLINE via PubMed using the following words, "probiotics", "prebiotics", "microbiota", and "gut-brain axis" in combination with "stress", "depression", "IBS", and "anxiety". A number of trials have shown efficacy of probiotics and prebiotics in ameliorating both IBS-related symptoms and emotional states. However, limitations have been found especially due to the small number of clinical studies, studies' design, patient sample size, and placebo effect. Summary Nonetheless, current finding supports the view that beneficial manipulation of the microbiota through both probiotics and prebiotics intake represents a novel attractive strategy to treat gut-brain axis disorders such as IBS and depression.
Introduction
The human gastrointestinal tract harbors trillions of microorganisms, with numbers recently estimated to be similar to the number of human cells in our bodies, and contains over 100 times more genes than the host genome [1••] . Nonetheless, the collective genome of these microorganisms has co-evolved with the host, contributing to its development and functioning [2] . Colonization of the gut commences at birth, during a crucial developmental window for the host, setting the stage for the establishment of a more complex microbiome in adulthood. More than 1000 species and 7000 strains have been identified as constituents of the adult microbiome. This ecosystem is dominated mainly by bacteria, but also contains viruses, protozoa, archaea, and fungi. The co-existence of the microbiome with the host establishes a long evolutionary symbiosis that is essential for optimal health throughout life. Indeed, essential processes, such as digestion [3] , immune responses [4, 5] , absorption of nutrients [3] , growth [6] , and metabolism [7] , are critically influenced by the microbiome. Moreover, an increasing body of evidence has highlighted a mutual influence between the microbiome and the brain [2, [8] [9] [10] [11] . The so-called gut-brain axis is a bidirectional communication system that enables gut microbes to communicate with the brain and the brain to communicate with the gut [9] . Perturbation of this axis has been shown to exacerbate vulnerability to a range of diseases ranging from visceral pain to mood disorders [2, [10] [11] [12] [13] [14] . Of importance, alterations in the richness and diversity of the microbiota have been observed in both depressed patients and individuals affected by irritable bowel syndrome (IBS) [15, 16] . Moreover, fecal microbiota transplantation from depressed patients into rodents can induce certain features characteristic of depression in the recipient animals, such as anhedonia and anxiety-like behaviors [17••] . Given this evidence, scientists have begun to believe that targeting the microbiota may open up novel strategies of prevention and intervention for a large spectrum of diseases that involve impairments both in the gut and in the brain. Of these novel strategies, probiotics, beneficial microorganisms believed to provide health benefits, and prebiotics, dietary soluble fibers that stimulate the growth of beneficial commensal microbiota, have been predominantly studied [18] . The current work aims to offer an updated review on the most recent findings in the field providing an overview of the efficacy of both probiotics and prebiotics in IBS and mood disorders such as anxiety and depression. The review also provides an understanding of the possible mechanisms that identify the routes of communication between the gut and the brain.
Probiotics and Prebiotics in IBS

Mono-Strain Probiotics
A number of clinical trials involving intervention using probiotics have demonstrated improvements in patients with IBS. Perhaps, the most compelling evidence demonstrating efficacy in the reduction of IBS symptoms comes from trials involving Bifidobacterium infantis 35624. A single center (77 IBS patients) and a multicenter trial (362 women with IBS) have both demonstrated efficacy in reducing pain, bloating, and improving bowel movements after 8 and 4 weeks of treatment over placebo, respectively [19, 20] . Moreover, such improvements were associated with the normalization of the ratio of the anti-inflammatory IL-10 to the pro-inflammatory IL-12 cytokines in the group receiving the probiotic compared to placebo [19] . Moreover, the fermented dairy product containing B. lactis DN-173010 (Activia, Danone) revealed improvements in accelerating gastrointestinal transit and in ameliorating distention after 4 weeks of a small single center (34 IBS patients), randomized controlled trial (RCT) [21] . However, two large multicenter trials (274 and 179 IBS patients, respectively) using the same fermented milk probiotic for a period of 6 and 12 weeks, respectively, were not able to show improvements in IBS symptoms over placebo [22, 23] . Of notice, Roberts and colleagues observed a 55% of withdrawals (76 out of 179 patients) at week 12. Therefore, the effect of the probiotic may have been missed due to lack of power.
Lactobacillus-containing probiotics have also been studied clinically. A RCT using Lactobacillus plantarum 299v (DSM 9843) ameliorated both abdominal pain and bloating over placebo after 4 weeks of treatment in 214 IBS patients fulfilling the Rome III criteria [24] . Moreover, L. plantarum 299v (DSM 9843) treatment could maintain a better overall gastrointestinal function in 60 IBS patients compared to placebo, which was observed 12 months after 4 weeks of probiotic administration [25] suggesting a long-lasting beneficial impact. In another trial, 4 weeks of L. acidophilus SDC 2012 and 2013 administration ameliorated abdominal pain in 40 IBS patients who met the Rome III criteria, compared to placebo [26] . A small-sized study of 55 IBS patients treated for 6 months with L. reuteri ATCC 5570 showed improvement in the global symptom score compared to baseline, but failed to demonstrate improvement over placebo due to a high placebo effect [27] . Interestingly, two different studies showed L. rhamnosus GG (LGG)-induced improvements in children with IBS (Rome II criteria). Children (104 and 141 pediatric IBS patients, respectively) were randomly assigned to receive either LGG or placebo for 4 or 8 weeks, respectively.
LGG administration reduced frequency of pain [28] and severity of pain [29] over placebo. However, a smaller RCT (55 children with IBS) showed that LGG was not superior to placebo in the treatment of abdominal pain but may help relieve such symptoms as perceived abdominal distention [30] .
The Escherichia coli DSM 17252 (Symbioflor 2) has also showed improvements in 298 IBS patients compared to placebo. After 8 weeks of treatment, both abdominal pain and general pain scores were significantly ameliorated in the IBS group [31] .
Multispecies Probiotics
Multispecies probiotics, defined as supplementations containing strains belonging to one or more genera, have also shown positive effects in patients with IBS (Table 1) . Two different RCTs used a combined supplementation of LGG, L. rhamnosus LC705, B. breve Bb99, and Propionibacterium freudenreichii spp. shermanii JS on 103 and 86 IBS patients (Rome II criteria), for a period of 6 and 5 months, respectively. In both studies, the gastrointestinal symptoms (abdominal pain, distension, flatulence, and borborygmi) were significantly reduced compared to placebo [32, 33] .
Similarly, 50 IBS patients were randomized into placebo or a multispecies probiotic product containing a mixture of L. acidophilus, L. plantarum, L. rhamnosus, B. breve, B. lactis, B. longum, and Streptococcus for a period of 8 weeks [34] . Although the probiotic mixture did not ameliorate abdominal pain, it significantly improved adequate relief of IBS symptoms when compared to placebo over time.
VSL#3, a probiotic supplementation made of B. longum, B. infantis, B. breve, L. acidophilus, L. casei, L. bulgaricus, L. plantarum, and Streptococcus salivarius subspecies thermophiles, has been largely investigated in several RCTs involving IBS patients. Eight weeks of However, the gut microbiota composition was not modified following treatment [35] . Kim and colleagues conducted three different studies in patients diagnosed with IBS according to the Rome II criteria. Eight weeks of VSL#3 treatment showed improvements in gastrointestinal symptoms over placebo, reducing flatulence score, abdominal pain, abdominal bloating, and slowing colonic transit without altering bowel function [36] [37] [38] . Furthermore, 59 children (age 4-15 years), selected in accordance to the Rome II criteria, reported gastrointestinal benefits after 6 weeks of VSL#3 treatment. Specifically, VSL#3 treatment effectively reduced abdominal pain/discomfort, abdominal bloating/gassiness, and family assessment of life disruption over placebo [39] .
Prebiotics
Few studies have evaluated the efficacy of prebiotics in reversing IBS symptoms in a clinical setting (Table 2) . One study showed the effects of fructooligosaccharides (FOS) in patients affected by minor functional bowel disorders (FBD; Rome II criteria). One hundred five IBS patients were randomized into two groups to receive either 5 g FOS or 5 g placebo over a 6-week period. At the end of the treatment period, the FOS group showed reduced incidence and intensity of gastrointestinal symptoms over placebo [40] . A smaller RCT investigated the effects of galactooligosaccharide (GOS) in 44 IBS patients fulfilling the Rome II criteria. Patients randomly received either 7 g/day placebo, 3.5 g/day GOS, and 3.5 g/day placebo or 7 g/day GOS for 6 weeks. The two prebiotic concentrations differentially improved IBS symptoms. Specifically, GOS 3.5 g/day improved flatulence, bloating, the composite score of symptoms, as well as subjective global assessment (SGA). GOS 7 g/day significantly improved SGA and anxiety symptoms as assessed by hospital anxiety and depression scale (HADS) [41] .
One of the complaints of prebiotic administration involves unwanted side effects associated with higher doses. For instance, daily treatment of 20 g/day FOS has been shown to worsen IBS symptoms (abdominal distension, abdominal rumbling, abnormal flatulence, and abdominal pain) compared to placebo during the first 6 weeks of treatment. However, continuous treatment for 12 weeks resulted in adaptation and no difference was found between groups [43] .
Overall, the clinical evidence accumulated to date characterizing the improvements of gastrointestinal and extraintestinal symptoms in patients with IBS following treatment with probiotics or prebiotics is limited. This is in part due to the small number of clinical studies, small sample size of the studies performed, and placebo effect. Specifically, subjective psychological symptoms in addition to the use of subjective measures of gastrointestinal function in IBS patients may further impact the observed placebo effect. Nonetheless, the data presented suggests possible benefits of specific probiotics and prebiotics in patients with IBS and further studies are highly recommended.
Probiotics and Prebiotics in Mood Disorders
Increasing evidence suggests that the microbiota is altered in patients with mood disorders, highlighting a role for the gutbrain axis in disease. With respect to treatment with either probiotics or prebiotics to modulate the microbiota, there is still a paucity of information that exists describing their effects FBD functional bowel disorders, sc-FOS short-chain fructo-oligosaccharides, SGA subjective global assessment, GOS galactooligosaccharide, HADS hospital anxiety and depression scale, qRT-PCR quantitative real-time polymerase chain reaction on anxiety and depression (Table 3) . One RCT investigated the effects of multispecies probiotic intervention on cognitive reactivity to sad mood in 40 healthy young students. Twenty participants were assigned to B. bifidum, B. lactis, L. acidophilus, L. brevis, L. casei, L. salivarius, and Lactococcus lactis multispecies probiotic supplementation, whereas 20 control participants received an inert placebo. After 4 weeks of treatment, the probiotic group showed reduced cognitive reactivity to sad mood (reduced aggressive thoughts and rumination) as assessed by the Leiden index of depression sensitivity-revised (LEIDS-R). Of note, eating habits were not reported in the study. Hence, it should be taken 10 days Barrier permeability, NF-kB expression, and IL-6, IL-4, IFN-y levels L. rhamnosus ↓ gut permeability, ↓ NF-kB expression, and ↓ cytokine production induced by DNBS [58] BALB/c mice L. casei, 10 8 cfu/m4 + acute stress (restrain stress) 11 days CD4+ and CD8+ T lymphocytes, CD11b+ macrophages, CD11c+ dendritic cells, IgA+ B lymphocytes, IgA and interferon gamma levels L. casei ↑ IgA producing cells, CD4+ cells in the lamina propria of the small intestine, and S-IgA in the lumen [59] CD1 mice B-GOS + LPS injection 3 weeks 5HT2A, 5HT1A, NMDA receptors and IL-1B cortical expression levels. Marble burying, light-dark box B-GOS ↓ anxiety-like behavior, altered cortical 5HT2A levels [60] C57BL/6J mice FOS, GOS, or the combination of the two 3 weeks Plasma corticosterone, microbiota composition, cSCFA. FUST, FST, tail suspension, 3-chambered social approach task, resident-intruder test GOS + FOS induced antidepressant and anxiolytic effects. GOS and GOS + FOS ↓ stress-induced corticosterone release. GOS + FOS altered hippocampal Gabbr1, Gabbr2, BDNF, Grin2a mRNA levels, ↑ cecal acetate and propionate, [61] into account that the potential consumption of other probiotics or fermented foods may have affected the final outcomes of the study [44] . Another RCT (66 healthy volunteers) showed that 30 days of L. helveticus R0052 and B. longum R0175 were able to mitigate psychological distress over placebo. Indeed, the probiotic group scored significantly better in the Hopkins Symptom Checklist (HSCL-90), the HADS, and the Coping Checklist (CCL). Moreover, cortisol levels, used as an index of stress response, were also reduced, supporting subjects' resilience to stress and improved emotional responses induced by probiotics [45, 52] . Similarly with prebiotics, a decrease in the neuroendocrine stress response in healthy subjects was observed after 3 weeks of Bimuno (B)-GOS treatment compared to placebo. Participants also demonstrated improved emotional attention as assessed by the attentional dot-probe task [46] . Probiotics have also been shown to beneficially modulate brain activity in female healthy subjects. Brain activity was evaluated in 23 women which following consumption of a fermented milk product containing B. animalis lactis, Streptococcus thermophiles, L. bulgaricus, and Lactococcus lactis (n = 12) or a non-fermented milk product (n = 11) for 4 weeks. Negative emotional faces, expressing fear and anger, were shown to the participants while brain activity was recorded by functional magnetic resonance imaging (fMRI). The activity of specific brain regions responsible for control of emotional processing, including the somatosensory cortex, the insula, and the periaqueductal gray, was markedly reduced by probiotic intake. The evidence sheds light on the ability of probiotics to modulate reactions to emotional stimuli in healthy individuals [47] .
L. casei Shirota, in the form of fermented milk, was evaluated for stress resilience in a double blind placebo-controlled trial. One hundred thirty-seven healthy medical students underwent daily treatment of probiotics over 8 weeks prior to academic examination. Salivary cortisol levels, physical symptoms, and a self-reported anxiety score were analyzed. Interestingly, L. casei Shirota attenuated the stress-induced increases in cortisol levels 1 day before examination and reduced the presence of physical symptoms along the last week of treatment [48••] .
In a study of major depressive disorder (MDD), 40 patients, as classified by the diagnostic and statistical manual of mental disorders (DSM)-IV criteria, were randomly assigned to 8 weeks of either L. acidophilus, L. casei, and B. bifidum probiotic supplementation or placebo. Interestingly, probiotic intervention significantly ameliorated the severity of depression as assessed by the Beck Depression Inventory (BDI) over placebo [49] . Similarly, the probiotic L. casei Shirota was evaluated in patients with chronic fatigue syndrome (CFS). CFS patients often manifest symptoms of depression and mood disorder [53] . CFS patients (n = 39) were randomly assigned to 8 weeks of probiotic treatment or placebo. Anxiety, but not depressive symptoms, was significantly reduced by L. casei intake as assessed by the Beck Anxiety Inventory (BAI) and BDI, respectively [50] .
One recent study has assessed the effects of consumption of probiotics in subjects genetically predisposed to develop social anxiety. Fermented food consumption, neuroticism, and social anxiety were self-reported by 715 participants (445 female). Social anxiety was significantly and independently predicted by exercise frequency, neuroticism, and fermented food consumption. Specifically, social anxiety symptoms were reduced by the consumption of probiotics in subjects at higher genetic risk of social anxiety, as indexed by high neuroticism traits [51] . Despite these promising findings to date, there is still limited evidence for the efficacy of probiotic and prebiotic intervention in patients with mood disorders. Additional clinical trials are critical prior to making any conclusions on the efficacy of probiotics and prebiotics in mental health.
Probiotics and Prebiotics: Gut-Brain Interaction
The crosstalk between the gut and brain has revealed a complex communication system, which is responsible for maintaining a proper gastrointestinal homeostasis as well as affecting emotional mood and cognitive functions. Although the gut-brain axis has been one of the main focuses of research in the last decades, the understanding of the role of the microbiota in modulating this signaling pathway is still at its infancy, (Table 4) . One of the most prominent studies in the field, conducted by Bravo and colleagues, revealed the vagus nerve as one of the principal routes of communication between the two systems. Indeed, the observed benefits exerted by the chronic administration of L. rhamnosus JB-1 in reducing anxiety-and depressive-like behaviors were vanished after vagotomy in mice. At the brain level, alterations in the expression of GABA receptors by probiotics in specific areas involved in the pathogenesis of anxiety, and depression disappeared in vagotomized mice [54] . Similarly, the administration of B. longum in an animal model of chronic colitis induced by dextran sodium sulfate (DSS) failed to reduce anxiety-like behavior in those mice that underwent vagotomy prior to induction of colitis [64] .
Another potential route through which the gut and the brain can interface is the immune system. Stress and bacterial antigens can increase the immune response to the luminal environment, inducing cytokine release in the blood stream. Although it is not clear yet whether cytokines can cross the blood-brain barrier (BBB) under these conditions, increasing evidence indicates that cytokines can influence brain areas, such as the hypothalamus, where the BBB is deficient. This is considered by most a plausible explanation of the observed activation of the hypothalamic-pituitary-adrenal (HPA) axis induced by pro-inflammatory cytokines and consequently corticosterone release, which is the most potent activator of the stress system. A number of probiotics belonging to the lactobacillus and bifidobacterium families have demonstrated the capability to restore corticosterone and adrenocorticotropic hormone (ACTH) plasma concentration as well as reduce hypothalamic corticotropin-releasing factor (CRF), interleukin (IL)-6, and tumor necrosis factor (TNF)-α levels, which were altered by both chronic stress and following increases in colonic permeability [55] [56] [57] [58] . One study showed that L. casei reinforced the immune system of adult mice subjected to chronic stress, increasing IgA-producing cells, CD4+ cells in the lamina propria of the small intestine, and secreted IgA in the lumen as well as reducing the levels of IFN-γ [59] . Similarly, administration of the prebiotics FOS and GOS demonstrated attenuation of stress-induced corticosterone levels, reduction of plasma pro-inflammatory cytokine levels, and decreased anxiolytic-like behavior in rodents [60, 61] .
In addition, evidence exists suggesting that probiotics can interact with the brain-gut axis through the regulation of neurotransmitter signaling. Specifically, B. infantis has been shown to regulate the serotonin (5-HT) system through the elevation of plasma tryptophan, a precursor of 5-HT [62] . It was also demonstrated that L. acidophilus may modulate intestinal dysfunction by inducing the expression of μ-opioid and cannabinoid receptors in intestinal epithelial cells [63] . Several bacterial species can also directly produce neurotransmitters such as 5-HT, γ-aminobutyric acid (GABA), dopamine, and acetylcholine in the lumen of the intestine [65] . However, it is believed that these neurotransmitters may have an indirect influence on brain function acting on the enteric nervous system, rather than crossing the BBB, which is highly unlikely [2] .
Bacterial metabolites represent another pathway of communication between the gut and the brain. One of the key products of bacterial metabolism is short-chain fatty acids (SCFAs) including butyric acid, propionic acid, and acetic acid. SCFAs have been shown to have a central effect, mostly influencing memory and learning processes through histone deacetylases modulation in rodents [66, 67] . SCFAs can also control body energy expenditure and maintain metabolic homeostasis binding specific G-protein-coupled receptors such as, GPR41 [68] . Probiotics have been shown to modify SCFA levels in both healthy adults [69] and patients affected by ulcerative colitis [70] . However, to our knowledge, there is a lack of evidence supporting the assumption of a strong correlation between probiotics and prebiotics, and the levels of SCFAs in either IBS or mood disorders [71] . Despite all the advances described above, our understanding of the mechanisms that outline the gut-brain communication urges to be further developed. A schematic representing the routes of communications between the gut and the brain is shown in Fig. 1 .
Conclusions
The impact of the gut microbiome on health, including mental health, is now a frontier research area that has caught the attention of the scientific community in a degree that has been rarely seen in other areas of science. The enthusiasm generated by a considerable number of preclinical data and supported by a growing clinical literature makes the microbiota an appealing therapeutic target for the prevention and treatment of various human diseases. In this review, we have provided evidence of the impact of probiotic and prebiotic treatments in both IBS and mood disorders such as anxiety and depression. Moreover, we have attempted to highlight the currently known routes of communication of the gut-brain axis. The evidence compiled in this review indicates that treatments with probiotics and prebiotics can ameliorate some of the symptomatology that characterizes both IBS and mood disorders such as anxiety and depression. Despite that, the evidence base is still limited, such as the small number of clinical studies, study design, size of the studies, and placebo effect has been highlighted throughout this work. Further clinical studies are required to shed light on the possible therapeutic effect exerted by both probiotics and prebiotics in health and mental health.
